



MAT Biopharma presented data on Ferritarg at AACR

Evry, France, April 16 2008 MAT Biopharma presented data at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) from its ongoing Phase I/II study of Ferritarg®, an antibody designed for the treatment of relapsed or refractory Hodgkin's disease.

Ferritarg is a radioimmunotherapeutic agent currently in Phase I/II in refractory Hodgkin's disease. Ferritarg binds to acid (H) iso-ferritin and is conjugated with Yttrium 90, which is a beta emitter, for therapeutic use.

Jean Kadouche, Chief Executive Officer commented, "Those results demonstrate that Ferritarg has a favorable tolerability and safety profile with an impressive tumor targeting (immunoscintigraphy with Indium 111). MAT Biopharma continues to make solid progress in the development of its product portfolio and notably Ferritarg®" About Hodgkin's disease

Hodgkin's disease, also known as Hodgkin's lymphoma, is a rare cancer of the lymphatic system. In Hodgkin's disease, cells in the lymphatic system grow abnormally and may spread beyond the lymphatic system. As Hodgkin's disease progresses, it compromises your body's ability to fight infection.

Hodgkin's disease most commonly affects people between the ages of 15 and 40 and people older than age 55. It's one of two common types of cancers of the lymphatic system. In the United States in 2004, there were about 7,880 new cases of Hodgkin's disease.

-Ends-

About MAT Biopharma.

MAT Biopharma is a privately held biopharmaceutical company focused on the development and commercialization of antibody based therapeutics for the treatment of haematological cancers and some solid tumors.

Note: Ferritarg® is a trademark of MAT Biopharma

Source : MAT Biopharma

Contact:

Frederic Gomez
Head of Corporate and Business Development
f.gomez@matbiopharma.fr